APP and Alzheimer disease: The results described above demonstrate that low expression levels of SORLA and SORCS1 causes pathogenic processing of APP by decreasing the time that APP resides in the TGN; therefore, we hypothesize that increasing expression of SORLA and SORCS1 or facilitating trafficking of these proteins from endosomes to the TGN might have protective effects against AD.